Diuretic therapy for critically ill patients: a systematic review and network meta-analysis
Pooled result · MortalityResult — go to the resultOdds ratio 1.26 95% CrI 0.62–2.55Authors' conclusion
Bolus loop diuretics were at least comparable to alternate diuretic strategies for patient important outcomes in critically ill adults, but this was based mostly on low or very low certainty evidence. Tolvaptan monotherapy may decrease acute kidney injury, but its effect on subsequent need for RRT and mortality remains uncertain.
Study context
- Population
- Critically ill adults requiring fluid removal
- Participants
- 1,652 adults · 26 RCTs
- Comparison
- Diuretic strategies for fluid removal
- Outcome
- Mortality
Methodological detailsrandom-effects, GRADE for network meta-analysis, ROBUST-RCT risk of bias
- Random-effects
- GRADE for network meta-analysis
- ROBUST-RCT risk of bias
Pooled result
As reported in the abstract
Odds ratio
1.26
95% CrI 0.62–2.55
Continuous loop infusion vs Bolus loop diuretics
OR 1.26 (95% CrI 0.62–2.55)
Further pooled results
| Outcome | MD (days) (95% CrI) | |
|---|---|---|
| ICU LOSContinuous loop infusion vs Bolus loop diuretics · CrI; low certainty · CrI | 1.56 (−0.02 to 3.16) | |
| −2024Difference, days (linear scale) |
| Outcome | OR (95% CrI) | |
|---|---|---|
| AKITolvaptan monotherapy vs Bolus or continuous loop diuretics · CrI; low certainty · CrI | 0.12 (0.01–0.87) | |
| 0.050.21520Odds ratio (log scale) |
AKI
- No studies evaluated tolvaptan's effect on need for RRT
Original publication
Diuretic therapy for critically ill patients: a systematic review and network meta-analysis. Ann Intensive Care. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →